Actively Recruiting
Registry Study of Prenatal Treatment for Spinal Muscular Atrophy Tracking Pregnancy and Child Outcomes After Disease-Modifying Therapy
Led by St. Jude Children's Research Hospital · Updated on 2026-10-22
30
Participants Needed
1
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
The research investigates cases of Spinal Muscular Atrophy SMA diagnosed before birth, focusing on the outcomes when pregnant women receive treatment to help their unborn babies. It aims to fill the gap in understanding the safety and potential benefits of treating SMA during pregnancy. This registry study will gather important information about pregnancy, delivery, and early childhood outcomes for mothers and babies affected by prenatal SMA treatment. Participants are mothers who have taken disease-modifying therapies such as risdiplam to treat their fetus diagnosed with SMA. The study will collect data retrospectively and prospectively from medical records, interviews, and surveys. Surveys will be completed at enrollment, shortly after delivery, and every six months for at least four years, following a three-year enrollment window. Throughout the study, researchers will monitor maternal-fetal health, pregnancy and delivery outcomes, and the clinical progress of children treated before birth. Data collection involves medical record review and questionnaires completed via email or interview. The study spans seven years, including a minimum four-year follow-up to assess long-term safety and benefit after birth.
CONDITIONS
Brief Title
A Registry of Cases of Spinal Muscular Atrophy
Research Team
R
Richard Finkel, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here